The ASCO Post Podcast

Latest Episodes:

Characteristics and Outcomes of Patients With Both COVID-19 and Cancer Apr 17, 2020

Show notes

To begin this week, we’ll discuss a report that focused on the characteristics and outcomes of patients with both COVID-19 and cancer in Wuhan, China. Next, we’ll turn to a paper on the efficacy of stereotactic ablative radiotherapy in men with oligometastatic prostate cancer. Lastly, we’ll talk about the FDA’s approval of encorafenib plus cetuximab in patients with BRAF V600E–mutated colorectal cancer.

Coverage of stories discussed this week on ascopost.com:

Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China

Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial

FDA Approves Encorafenib/Cetuximab for BRAF V600E–Mutated Metastatic Colorectal Cancer

Report on the ASH COVID-19 Registry for Malignant Hematology Apr 13, 2020

Show notes

We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative’s Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we’ll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week’s episode, we’ll go over the FDA’s approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

End-of-Trial Findings From CLEOPATRA Apr 06, 2020

Show notes

This week, we’ll start with a report on end-of-trial findings with a triplet combination treatment for HER2-positive metastatic breast cancer. Then, we’ll hear from the director of a comprehensive cancer center on how her institution is handling the coronavirus outbreak. Lastly, we’ll discuss the FDA’s approval of durvalumab in small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC

Cancer Care Amid the COVID-19 Pandemic Mar 27, 2020

Show notes

To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy is addressing the needs of patients with cancer. Lastly, we’ll go over a paper about the reintroduction of a combination regimen when disease progresses after upfront treatment in patients with colorectal cancer.

Coverage of stories discussed this week on ascopost.com:

Managing Cancer Care During the COVID-19 Pandemic

Reintroduction of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Coronavirus, Patients With Cancer, and the Preparedness of the Institutions That Care for Them Mar 19, 2020

Show notes

We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.

Coverage of stories discussed this week on ascopost.com:

Mitigating the Spread of COVID-19 and Its Impact on Cancer

COVID-19 Infection in Patients With Cancer in China

FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma

Pulmonary Pathology of the Novel Coronavirus in Two Patients With Lung Cancer Mar 13, 2020

Show notes

We’ll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We’ll also update you as to upcoming oncology meetings that have been cancelled due to concerns about the virus.
We’ll then turn to a report that found adjuvant gemcitabine/platinum chemotherapy was associated with improved disease-free survival vs surveillance in patients with locally advanced urothelial carcinoma of the upper urinary tract.
Finally, we’ll hear a summary of an important talk given at the recent ASCO-SITC Immuno-Oncology Symposium.

Coverage of stories discussed this week on ascopost.com:

Pulmonary Pathology of Early COVID-19 Pneumonia Identified Retrospectively in Two Patients With Lung Cancer

Adjuvant Gemcitabine/Platinum-Based Chemotherapy vs Surveillance for Upper Tract Urothelial Carcinoma: POUT Trial

News From the 2020 Multidisciplinary Head and Neck Cancers Symposium Mar 06, 2020

Show notes

This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma

News From the Genitourinary Cancers Symposium Feb 27, 2020

Show notes

This week, we’ll be reviewing data from three influential abstracts presented at the recent 2020 Genitourinary Cancers Symposium in San Francisco—one on a novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha inhibitor for heavily pretreated patients with metastatic clear cell renal cell carcinoma; the second, on whether pembrolizumab in combination with the antibody-drug conjugate enfortumab vedotin may be an alternative option for platinum-ineligible patients with locally advanced or metastatic urothelial carcinoma; and the third, on treatment with pembrolizumab plus enzalutamide after disease progression on enzalutamide in patients with castration-resistant prostate cancer.

Pembrolizumab Plus Chemotherapy in HER2-Negative Breast Cancer Feb 21, 2020

Show notes

We’ll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we’ll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we’ll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

H pylori Infection and Gastric Cancer Risk Feb 14, 2020

Show notes

First, we’ll discuss a Korean trial that looked at the role of H pylori infection and gastric cancer risk. Next, we’ll turn to a modeling study that examined HPV vaccination and cervical cancer incidence in low-income and lower–middle-income countries. Last this week, we’ll look at data presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on reducing the risk for immune checkpoint inhibitor–associated colitis.

Coverage of stories discussed this week on ascopost.com:

Does Treating Individuals for H pylori Infection Reduce Gastric Cancer Risk in Those With a Family History of the Disease?

Modeling the Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination in Low-Income and Lower-Middle–Income Countries